Top Page
GlaxoSmithKline
(LSE:GSK)
GlaxoSmithKline (GSK) vs. iShares MSCI United Kingdom ETF (EWC)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.63B | 31.38B | 30.33B | 29.32B | 24.70B | 34.10B |
| Gross Profit | 22.68B | 21.90B | 21.25B | 19.46B | 16.34B | 23.12B |
| EBITDA | 9.08B | 6.67B | 9.14B | 8.63B | 6.45B | 10.16B |
| Net Income | 3.42B | 2.58B | 4.93B | 14.96B | 4.38B | 5.75B |
Balance Sheet | ||||||
| Total Assets | 59.26B | 59.46B | 59.01B | 60.15B | 79.10B | 80.43B |
| Cash, Cash Equivalents and Short-Term Investments | 3.62B | 3.89B | 5.69B | 7.88B | 4.33B | 6.37B |
| Total Debt | 17.35B | 16.99B | 18.02B | 20.99B | 24.17B | 27.15B |
| Total Liabilities | 44.90B | 46.38B | 46.21B | 50.05B | 57.76B | 59.62B |
| Stockholders Equity | 14.79B | 13.67B | 13.35B | 10.60B | 15.05B | 14.59B |
Cash Flow | ||||||
| Free Cash Flow | 5.20B | 3.57B | 4.42B | 5.14B | 5.02B | 6.20B |
| Operating Cash Flow | 7.72B | 6.55B | 6.77B | 7.40B | 7.95B | 8.44B |
| Investing Cash Flow | -3.62B | -1.23B | -1.59B | -8.77B | -1.78B | 2.16B |
| Financing Cash Flow | -3.60B | -4.73B | -5.64B | 823.00M | -7.59B | -10.13B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £58.50B | 17.29 | 23.47% | 3.96% | 0.59% | -15.36% | |
76 Outperform | £11.92B | 31.49 | 9.30% | 2.29% | 2.51% | 56.56% | |
73 Outperform | £182.65B | 28.45 | 20.09% | 1.75% | 11.89% | 25.68% | |
70 Outperform | £4.00B | 14.01 | 15.66% | 3.51% | 3.73% | 27.13% | |
64 Neutral | £4.72B | 28.23 | 12.73% | 2.06% | 4.18% | 37.65% | |
54 Neutral | €4.17B | 12.59 | -36.14% | 2.46% | 15.95% | -24.06% |
GlaxoSmithKline Corporate Events
GSK has announced the purchase of 436,588 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement, increases the total number of shares held in treasury to 242,277,376, representing 5.95% of the company’s voting rights. The buyback is intended to optimize the capital structure and return value to shareholders, reflecting GSK’s confidence in its financial health and future prospects.
GlaxoSmithKline (GSK) has announced the repurchase of 501,689 of its ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares. This transaction is part of a non-discretionary agreement initiated on June 4, 2025, and contributes to the total of 23,706,405 shares repurchased since that date. The buyback program aims to manage the company’s capital structure effectively, impacting the total number of voting rights, which stands at 4,073,550,458.
GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a larger effort that has seen the company buy back over 23 million shares since June 2025. The purchased shares will be held as treasury shares, and this move is expected to impact the company’s share capital structure by adjusting the number of voting rights, which now stands at 4,074,052,147.
GSK has announced the purchase of 495,245 of its own ordinary shares as part of its ongoing buyback program, executed through its broker, Merrill Lynch International. This transaction, which took place on 12 August 2025, is part of a larger initiative that has seen the company repurchase over 22 million shares since June 2025. The shares will be held as treasury shares, impacting the company’s voting rights and share capital structure, with implications for shareholder interests and market positioning.
GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of 18 ordinary shares at a price of £14.0845 per share by each executive. This move reflects the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence and reinforcing GSK’s market position.
GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of an ongoing buyback program, executed through Merrill Lynch International. This transaction is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value, with the purchased shares being held as treasury shares. The buyback program reflects GSK’s confidence in its financial health and its commitment to delivering value to its shareholders.
GSK has announced the purchase of 497,923 of its own ordinary shares as part of its ongoing share buyback program, executed through Merrill Lynch International. This transaction, which took place on August 8, 2025, reflects GSK’s strategic efforts to manage its capital structure and return value to shareholders. The shares were acquired at prices ranging from 1,389.50p to 1,405.50p and will be held as treasury shares, contributing to a total of 240,042,950 shares held in treasury. This move is part of a broader plan initiated on June 4, 2025, and highlights GSK’s commitment to enhancing shareholder value while maintaining a robust financial position.
GSK announced that the US FDA has accepted gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea, with a decision expected in December 2025. This new antibiotic option could replace current injectable treatments, addressing a significant public health need as gonorrhoea is a priority pathogen with rising resistance to existing therapies.
GlaxoSmithKline (GSK) has announced the purchase of 502,466 of its own ordinary shares as part of its ongoing buyback program, executed through its corporate stockbroker Merrill Lynch International. This transaction is part of a non-discretionary agreement made on June 4, 2025, and contributes to the total of 21,410,644 shares purchased since that date. The purchased shares will be held as treasury shares, and this move is expected to impact the company’s share capital structure by maintaining a percentage of voting rights attributable to treasury shares at 5.88%.
GSK has announced a settlement with CureVac and BioNTech regarding mRNA patent litigation, resulting in a $370 million upfront payment and a 1% royalty on future US sales of mRNA vaccines by Pfizer and BioNTech. This settlement, which will be recorded in GSK’s financial results, does not affect GSK’s ongoing patent enforcement against Pfizer and BioNTech in the US and Europe, and includes a tender agreement for GSK’s CureVac shares.
GlaxoSmithKline (GSK) has announced the purchase of 504,016 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on August 6, 2025, is part of a non-discretionary agreement with the broker and contributes to the company’s strategy of managing its capital structure. The shares will be held as treasury shares, and following this purchase, GSK holds 239,042,561 ordinary shares in treasury, with a total of 4,076,345,924 ordinary shares in issue. This move is significant for shareholders as it impacts the voting rights and shareholding calculations under the Financial Conduct Authority’s rules.
GSK has announced the repurchase of 498,759 of its own shares as part of its ongoing buyback program, facilitated through Merrill Lynch International. This transaction, executed on August 5, 2025, reflects the company’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and this move increases the total number of shares held in treasury to 238,538,545, representing 5.85% of the voting rights. This buyback is part of a broader effort to enhance shareholder value and optimize the company’s financial resources.
GSK has announced the repurchase of 499,189 of its ordinary shares as part of its ongoing buyback program. The shares were purchased at a volume-weighted average price of 1,391.81 pence and will be held as treasury shares. This transaction is part of a non-discretionary agreement with Merrill Lynch International, aiming to optimize the capital structure and return value to shareholders.
GSK has announced the purchase of 496,176 of its own ordinary shares, which will be held as treasury shares, as part of its ongoing buyback program. This move, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders, potentially impacting the company’s stock value and market perception.
GSK plc announced its total voting rights and capital structure as of July 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company reported an issued share capital of over 4.3 billion shares, with a total of approximately 4.08 billion voting rights available. This information is crucial for shareholders to determine their interests and obligations under regulatory guidelines.
GSK has announced the purchase of 474,100 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 237,044,421 shares in treasury, representing 5.81% of the voting rights. The buyback program reflects GSK’s commitment to returning value to shareholders and optimizing its financial position.
GSK has announced the purchase of 474,100 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, aims to enhance shareholder value and manage the company’s capital structure effectively. Following this purchase, GSK holds 237,044,421 shares in treasury, with a total of 4,078,340,989 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.
GlaxoSmithKline (GSK) plc, a major player in the pharmaceutical industry, has announced the purchase of 288,978 of its own ordinary shares, as part of its ongoing share buyback program. The shares were acquired through Merrill Lynch International, with prices ranging from 1,386.50p to 1,463.50p per share. This move is part of GSK’s strategy to manage its capital structure and return value to shareholders. Following this transaction, GSK holds 236,570,321 shares in treasury, with a total of 4,078,815,089 shares in issue, excluding treasury shares. The percentage of voting rights attributable to the shares held in treasury is now 5.80%.
GSK announced the repurchase of 490,615 of its own shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This transaction is part of a larger initiative that has seen the company buy back over 18 million shares since June 2025, reflecting GSK’s strategy to optimize its capital structure and enhance shareholder value.
GSK reported strong financial performance in Q2 2025, driven by significant growth in its Specialty Medicines and Vaccines segments, with sales reaching £8.0 billion. The company achieved major milestones in its R&D pipeline, including several new product approvals and ongoing development of promising treatments in oncology and respiratory diseases. GSK has revised its 2025 financial guidance upwards, expecting growth towards the top end of its previous estimates, and continues to focus on shareholder returns through dividends and a share buyback program.
GSK announced the purchase of 490,978 of its own ordinary shares as part of its ongoing buyback program. This move, executed through Merrill Lynch International, aims to manage the company’s capital structure and potentially enhance shareholder value. The shares will be held in treasury, and following this transaction, GSK holds a total of 235,790,728 shares in treasury, representing 5.78% of the voting rights. This strategic buyback is part of a broader effort to optimize financial performance and maintain a favorable market position.
GSK has entered into agreements with Hengrui Pharma to develop up to 12 innovative medicines in the fields of Respiratory, Immunology & Inflammation, and Oncology, with a significant focus on a potential best-in-class PDE3/4 inhibitor for COPD treatment. This collaboration, which includes a $500 million upfront payment and potential future milestone payments of up to $12 billion, aims to leverage GSK’s global scale and Hengrui’s early discovery capabilities to accelerate the development and commercialization of these therapies, potentially enhancing GSK’s market position and offering new treatment options for patients worldwide.
GSK announced the purchase of 491,631 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of an agreement from June 2025, increases GSK’s treasury shares to 234,811,740, with the total number of voting rights remaining at 4,080,572,540. The buyback is a strategic move to manage the company’s capital structure and potentially enhance shareholder value.
GSK announced the approval of Blenrep combinations in the European Union for treating relapsed or refractory multiple myeloma, based on superior efficacy demonstrated in the DREAMM-7 and DREAMM-8 phase III trials. This approval marks a significant advancement in multiple myeloma treatment, offering a differentiated mechanism of action and broad accessibility, potentially extending remission and survival for patients. The approval positions GSK strongly in the oncology market, with applications for Blenrep under review in major global markets, highlighting its potential impact on patient care and the company’s market positioning.
GlaxoSmithKline (GSK) has announced the purchase of 491,680 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Merrill Lynch International, were bought at prices ranging from 1,364.50p to 1,374.50p, with a volume-weighted average price of 1,369.42p. These shares will be held as treasury shares, increasing GSK’s total treasury holdings to 234,320,109 shares. This move is part of a non-discretionary agreement with the broker, which began on June 4, 2025, and has so far seen the purchase of over 16 million shares. The total number of voting rights in the company remains at 4,081,064,171.
GSK announced that the FDA has extended the review period for the Biologics License Application for Blenrep combinations, used in treating relapsed or refractory multiple myeloma. The extension allows the FDA more time to review additional information, with a new action date set for October 23, 2025. The application is backed by positive results from the DREAMM-7 and DREAMM-8 trials, which demonstrated significant improvements in progression-free survival and overall survival rates. Blenrep combinations are already approved in several countries, and applications are under review in major global markets, potentially impacting GSK’s market positioning and offering new treatment options for multiple myeloma patients.
GSK has announced the purchase of 506,734 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. These shares will be held as treasury shares, increasing the total to 233,828,429, while the company has 4,081,555,851 shares in issue. This move is part of a non-discretionary agreement to enhance shareholder value, reflecting GSK’s strategic financial management and its impact on voting rights, now at 5.73% for treasury shares.
GSK has announced the purchase of 504,228 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which follows a non-discretionary agreement from June 2025, increases GSK’s treasury shares to 233,321,695. The buyback strategy is aimed at optimizing capital structure and potentially enhancing shareholder value, as the company now holds 5.72% of its shares in treasury.
GSK has announced the purchase of 505,771 of its own ordinary shares as part of its ongoing buyback program, executed through its broker, Merrill Lynch International. This transaction is part of a non-discretionary agreement and contributes to the company’s strategy to manage its capital structure, holding a total of 232,817,467 shares in treasury, which represents 5.70% of the voting rights.
GSK has announced the acquisition of American Depositary Shares (ADSs) by key executives, including Dr. Hal Barron, James Ford, and Shobie Ramakrishnan, following the reinvestment of dividends paid to shareholders. These transactions, conducted on the New York Stock Exchange, reflect a strategic move to enhance shareholder value and demonstrate confidence in the company’s future performance.
GSK announced that the FDA’s Oncologic Drugs Advisory Committee voted against the benefit/risk profile of Blenrep combinations for relapsed/refractory multiple myeloma at the proposed dosage. Despite this, GSK remains confident in Blenrep’s potential and continues to collaborate with the FDA, emphasizing the high unmet need for novel treatments in this area. Blenrep combinations have already been approved in several markets, including the UK and Japan, and are under review globally. The announcement highlights the challenges and ongoing efforts in providing effective treatments for multiple myeloma, a significant health concern with limited curative options.
GSK has announced the purchase of 484,633 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This move, which is part of a non-discretionary agreement, increases the total number of shares held in treasury to 232,311,696, representing 5.69% of the company’s voting rights. The buyback is a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
GSK announced that the US FDA has approved a prefilled syringe presentation of Shingrix, its shingles vaccine, simplifying administration for healthcare professionals. This development is expected to enhance the vaccination process, potentially increasing immunization rates among adults over 50 and those at higher risk due to immunodeficiency. The approval aligns with GSK’s commitment to advancing scientific innovation and addressing healthcare needs, with further regulatory reviews underway in Europe.
GlaxoSmithKline (GSK) has announced the purchase of 482,507 of its own ordinary shares, as part of its ongoing share buyback program. The shares, purchased at a volume-weighted average price of 1,419.08 pence, will be held as treasury shares. This transaction, executed through Merrill Lynch International, is part of a non-discretionary agreement initiated on June 4, 2025. Following this purchase, GSK holds 231,827,063 shares in treasury, with 4,083,556,994 shares in issue, excluding treasury shares. The buyback program aims to manage the company’s capital structure and return value to shareholders.
GSK has announced the purchase of 487,387 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This move, which is part of a non-discretionary agreement, aims to consolidate the company’s share capital and potentially enhance shareholder value. Following this transaction, GSK holds 231,344,556 shares in treasury, with a total of 4,084,039,501 shares in issue, excluding treasury shares. The buyback reflects GSK’s strategic focus on optimizing its capital structure and returning value to its shareholders.
GSK plc announced the acquisition of ordinary shares by several senior executives and associated persons following the reinvestment of dividends paid to shareholders on July 10, 2025. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence and reinforcing its market position.
GSK announced the purchase of 482,889 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which follows a non-discretionary agreement made in June 2025, increases the company’s treasury shares to 230,857,169 and maintains the total number of voting rights at 4,084,526,888. This strategic move is part of GSK’s efforts to manage its capital structure and potentially enhance shareholder value.
GSK plc has announced the acquisition of ordinary shares by several of its senior executives under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involves key figures such as the CEO, CFO, and other senior vice presidents, reflecting the company’s commitment to aligning leadership interests with shareholder value. The acquisition of shares at a price of £14.2073 each signifies a strategic move to enhance stakeholder confidence and strengthen the company’s market position.
GSK has announced the purchase of 486,127 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. Following this purchase, GSK holds 230,374,280 shares in treasury, with a total of 4,085,009,777 ordinary shares in issue. The buyback program aims to optimize the company’s financial flexibility and strengthen its market position.
GSK has announced that the US FDA has accepted its application to expand the use of its RSV vaccine, Arexvy, to adults aged 18-49 who are at increased risk of severe RSV infection. This submission is backed by positive Phase IIIb trial data demonstrating the vaccine’s immune response and safety in this demographic. The FDA’s decision is expected in the first half of 2026. This expansion could significantly impact GSK’s market positioning by broadening its vaccine’s target demographic, potentially increasing its market share and providing enhanced protection against RSV for millions of at-risk adults.
GSK announced the purchase of 335,358 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of a non-discretionary agreement, increases the company’s treasury shares to 229,888,153, with a total of 4,085,493,697 shares in issue. The buyback program is a strategic move to manage the company’s capital structure and potentially enhance shareholder value.
GSK plc has announced the repurchase of 473,780 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which involved purchasing shares at prices ranging from 1,403.50p to 1,430.00p, is part of a strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 229,552,795 shares in treasury, representing 5.62% of the voting rights, and maintains a total of 4,085,829,055 shares in issue. This move is likely to impact the company’s stock liquidity and shareholder value positively.
GSK has announced a purchase of 480,940 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on 8 July 2025, is part of a non-discretionary agreement and contributes to the company’s strategy of managing its capital structure effectively. The shares will be held in treasury, increasing the total to 229,079,015, while maintaining 4,086,302,835 shares in issue. This move is likely to impact shareholder value positively by reducing the number of shares available in the market, potentially increasing earnings per share.
GSK has announced the purchase of 485,199 of its own ordinary shares as part of its ongoing buyback program, facilitated by Merrill Lynch International. This transaction, executed on the London Stock Exchange, reflects GSK’s strategic initiative to manage its capital structure and enhance shareholder value, with the purchased shares being held as treasury shares. The buyback program, initiated in June 2025, has seen the company acquire over 10 million shares, indicating a strong commitment to returning value to shareholders.
GSK has completed the acquisition of efimosfermin alfa from Boston Pharmaceuticals, a move that significantly expands its hepatology pipeline. Efimosfermin, a potential best-in-class medicine for steatotic liver disease, is in phase III development and aims to address unmet needs in metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease. The acquisition, valued at up to $2 billion, underscores GSK’s commitment to innovation in fibro inflammatory diseases, with a potential first launch in 2029.
GSK has announced the purchase of 484,578 of its own ordinary shares as part of its ongoing share buyback program. This transaction, executed through Merrill Lynch International, is part of a non-discretionary agreement initiated on June 4, 2025. The shares will be held as treasury shares, and the purchase aims to optimize the company’s capital structure, potentially enhancing shareholder value by reducing the number of shares in circulation.
GlaxoSmithKline (GSK) has announced the purchase of 479,429 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Merrill Lynch International, will be held as treasury shares. This transaction is part of a non-discretionary agreement established on June 4, 2025, and contributes to the company’s strategy to manage its capital structure. Following this purchase, GSK holds 227,136,326 shares in treasury, with 4,088,233,873 shares in issue. The buyback program is a strategic move to enhance shareholder value and optimize the company’s financial position.
GSK announced the purchase of 484,326 of its own ordinary shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This transaction is part of a non-discretionary agreement and contributes to the company’s strategy to manage its capital structure, potentially enhancing shareholder value by reducing the number of shares in circulation.
GSK plc has announced the total voting rights and capital for the company as of June 30, 2025. The company’s issued share capital consists of over 4.3 billion ordinary shares, with approximately 226 million held in treasury, resulting in a total of over 4 billion voting rights. This information is crucial for shareholders to determine their interest in the company according to the Financial Conduct Authority’s rules.
GSK has announced the purchase of 483,834 of its own ordinary shares as part of its ongoing share buyback program. This move, executed through Merrill Lynch International, aims to consolidate the company’s share capital and potentially enhance shareholder value by holding these shares in treasury, which now totals 226,172,571 shares. The transaction reflects GSK’s strategic financial management and may impact shareholder voting rights, with the current percentage of voting rights attributable to treasury shares standing at 5.53%.
GSK has announced the purchase of 482,114 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on the London Stock Exchange, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, with a total of 7,554,354 shares bought back since June 4, 2025. The shares will be held in treasury, affecting the total number of voting rights and potentially impacting shareholder calculations under regulatory guidelines.
GlaxoSmithKline (GSK) has announced a purchase of 485,032 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at prices ranging from 1,390.00p to 1,405.00p, will be held as treasury shares. This transaction, executed through Merrill Lynch International, is part of an agreement initiated on 4 June 2025. Following this purchase, GSK holds 225,206,623 shares in treasury, with a total of 4,090,138,849 shares in issue. The buyback program is aimed at optimizing the company’s capital structure and providing value to shareholders.
GSK has announced the purchase of 483,629 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and this move is likely to impact the company’s share value and voting rights, with 5.49% of voting rights now attributable to treasury shares.
GlaxoSmithKline (GSK) has announced the purchase of 476,537 of its own ordinary shares, as part of its ongoing buyback program. The shares, bought at prices ranging from 1,403.50p to 1,421.50p, will be held as treasury shares. This move is part of a non-discretionary agreement with Merrill Lynch International, which has been in effect since June 4, 2025. Following this transaction, GSK holds 224,237,962 shares in treasury, which represents 5.48% of the company’s voting rights. This buyback initiative is likely aimed at consolidating GSK’s market position and optimizing shareholder value.
GSK plc announced a series of transactions involving Sally Jackson, SVP of Global Communications & CEO Office, and her closely associated person, Dylan Jackson. The transactions included gifting shares, selling shares to facilitate ISA transfers, and purchasing shares into an ISA. These movements, conducted on the London Stock Exchange, reflect personal financial management strategies by key personnel, potentially impacting internal shareholding structures.
GlaxoSmithKline (GSK) announces a significant leadership change as Wendy Becker, a Non-Executive Director and Chair of the Remuneration Committee at GSK, has been appointed as the Chair of the Board of Sony Group Corporation. This appointment reflects Becker’s growing influence and leadership within the corporate sector, potentially enhancing GSK’s strategic connections and influence in the global market.
GSK plc has announced the purchase of 483,823 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on June 23, 2025, is part of a non-discretionary agreement with the broker and contributes to the company’s strategy to manage its capital structure. Following this purchase, GSK holds 223,761,425 shares in treasury, with 4,091,584,047 shares in issue. The buyback program may impact shareholder value and voting rights, as the percentage of voting rights attributable to treasury shares is now 5.47%.
GlaxoSmithKline (GSK) announced a series of share purchases by its directors and persons closely associated with them. Notable transactions include Lady Susan Symonds purchasing 1,350 ordinary shares, while other directors such as Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr. Hal Barron, Dr. Anne Beal, and Dr. Hal Dietz also acquired shares or American Depositary Shares (ADSs) on the London and New York Stock Exchanges. These transactions reflect confidence in the company’s future prospects and may influence stakeholder perceptions.
GSK plc announced the purchase of shares by several of its non-executive directors, including Sir Jonathan Symonds and Wendy Becker, among others. These transactions, involving both Ordinary Shares and American Depositary Shares, were conducted on the London Stock Exchange and the New York Stock Exchange. The purchases indicate a vote of confidence from the company’s leadership in GSK’s future prospects and may positively influence investor sentiment.
GSK announced that the European Medicines Agency has accepted the marketing authorisation application for linerixibat, a targeted inhibitor for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). This follows the FDA’s acceptance earlier, highlighting linerixibat’s potential to address the unmet medical need for effective treatments for PBC-related relentless itch and sleep disruption. The application is based on positive results from the GLISTEN phase III trial, which showed significant improvements in pruritus and sleep interference. If approved, linerixibat could significantly impact GSK’s operations and market positioning by providing a novel treatment option for PBC patients.
GSK announced that the European Medicines Agency has accepted the marketing authorisation application for linerixibat, a targeted inhibitor for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). This development follows FDA acceptance and is based on positive results from the GLISTEN phase III trial, which showed significant improvement in symptoms. If approved, linerixibat could provide relief for patients with this rare autoimmune liver disease, addressing a high unmet medical need and potentially enhancing GSK’s position in the hepatology market.
GSK plc announced the purchase of 478,383 of its own ordinary shares as part of its existing buyback program, executed through Merrill Lynch International. This move is part of a strategy to manage the company’s capital structure and potentially enhance shareholder value, with the purchased shares held as treasury shares. The transaction underscores GSK’s commitment to optimizing its financial operations and maintaining a robust market position.
GSK has announced the repurchase of 473,254 of its ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares. This transaction is part of a broader strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 222,799,219 shares in treasury, with a total of 4,092,502,370 shares in issue. The buyback program reflects GSK’s commitment to enhancing shareholder value and optimizing its financial structure.
GSK announced that Japan’s Ministry of Health, Labour and Welfare has accepted its application to expand the use of its RSV vaccine, Arexvy, to adults aged 18-49 at increased risk of severe RSV disease. This expansion, supported by positive Phase IIIb trial data, would make Arexvy the first vaccine available in Japan for this age group, potentially strengthening GSK’s market position in the RSV vaccine sector and offering new protection options for at-risk populations.
GSK announced that Japan’s Ministry of Health, Labour and Welfare has accepted its application to expand the use of its RSV vaccine, Arexvy, to adults aged 18-49 at increased risk of severe RSV disease. This expansion, if approved, would make Arexvy the first vaccine available in Japan for this demographic, supported by positive Phase IIIb trial data. The move positions GSK as a leader in RSV prevention, with ongoing regulatory submissions in the US and Europe, potentially impacting its market presence and providing broader protection against RSV globally.
GSK has announced the repurchase of 468,255 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on June 18, 2025, forms part of a strategic initiative to manage the company’s capital structure and potentially enhance shareholder value. Following this purchase, GSK holds 222,325,965 shares in treasury, with a total of 4,092,975,624 shares in issue, excluding treasury shares. The buyback reflects GSK’s commitment to returning value to its shareholders and maintaining a robust financial position.
GSK plc announced the purchase of 458,818 of its ordinary shares as part of its ongoing share buyback program. The shares, bought at prices ranging from 1,465.00p to 1,485.00p, will be held as treasury shares. This move is part of a non-discretionary agreement with Merrill Lynch International, and it increases the total number of shares held in treasury to 221,857,710. The buyback program is a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
GSK has announced the repurchase of 453,531 of its ordinary shares as part of its ongoing buyback program. The shares were purchased at prices ranging from 1,485.50p to 1,506.00p and will be held as treasury shares. This move, facilitated by Merrill Lynch International, is part of a strategy to manage the company’s capital structure and return value to shareholders. Following this transaction, GSK holds 221,398,892 shares in treasury, with a total of 4,093,902,697 shares in issue. The buyback program reflects GSK’s commitment to optimizing shareholder returns and maintaining a robust financial position.
GSK has announced the purchase of 356,703 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction aims to consolidate the company’s share capital and potentially enhance shareholder value. Following this purchase, GSK holds 220,945,361 shares in treasury, with a total of 4,094,356,228 shares in issue, impacting the percentage of voting rights and potentially influencing shareholder decisions under regulatory guidelines.
GSK plc announced a transaction involving the sale of 29,763 ordinary shares by Sally Jackson, the Senior Vice President of Global Communications and CEO Office. The transaction was conducted on the London Stock Exchange at a price of £15.4447 per share. This sale may have implications for GSK’s stock market activity and could be of interest to stakeholders monitoring executive transactions within the company.
GSK announced that the European Medicines Agency has accepted its application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This expansion could significantly impact GSK’s operations and industry positioning by broadening the vaccine’s market reach, potentially benefiting stakeholders by addressing a common virus that affects millions globally. A decision is anticipated in the first half of 2026, and GSK is also seeking similar approvals in the US and Japan.
GlaxoSmithKline (GSK) has announced the purchase of 317,488 of its own ordinary shares as part of its ongoing buyback program. These shares will be held as treasury shares, and the transaction was conducted through Merrill Lynch International. This move is part of a non-discretionary agreement with the broker, initiated on June 4, 2025. Following this purchase, GSK now holds 220,588,658 shares in treasury, with a total of 4,094,694,253 ordinary shares in issue. The buyback is expected to impact the company’s financial structure by potentially increasing shareholder value and optimizing capital allocation.
GSK announced the purchase of 325,916 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement, increases the total shares held in treasury to over 220 million, representing 5.38% of the company’s voting rights. The buyback is a strategic move to enhance shareholder value and manage capital structure, reflecting positively on GSK’s financial health and market confidence.
GSK plc announced the sale of 30,000 ordinary shares by James Ford, the Senior Vice President and Group General Counsel for Legal and Compliance. The transaction, conducted on the London Stock Exchange, reflects internal financial activities and may influence stakeholder perceptions regarding the company’s financial strategies.
GSK has announced the purchase of 374,145 of its ordinary shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This move is part of a non-discretionary agreement and aims to consolidate the company’s shareholding structure, holding these shares in treasury, which now account for 5.37% of the voting rights. This strategic buyback is expected to enhance shareholder value and optimize the company’s capital structure.
GlaxoSmithKline has announced the repurchase of 348,430 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on June 9, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and following this purchase, GSK holds 219,571,109 ordinary shares in treasury. The buyback program is expected to enhance shareholder value and optimize the company’s financial position.
GSK plc announced the purchase of 342,461 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares, increasing the total number of shares held in treasury to 219,222,679. This action is part of a non-discretionary agreement and reflects the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GSK has announced the repurchase of 355,835 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders, holding 218,880,218 shares in treasury post-purchase. The buyback could potentially enhance shareholder value and influence the company’s stock market performance.
GSK has announced the repurchase of 390,000 of its own ordinary shares as part of its ongoing buyback program. The shares were acquired at prices ranging from 1,476.50p to 1,500.00p and will be held as treasury shares, which currently account for 5.33% of the company’s voting rights. This move is part of GSK’s strategy to enhance shareholder value and manage its capital structure effectively.
GSK has announced the purchase of 417,924 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, and the total number of voting rights remains unchanged, allowing stakeholders to assess their interests in the company accurately.
GSK has announced the launch of the second tranche of its £2 billion share buyback program, which aims to return excess capital to shareholders and enhance earnings per share. This tranche, valued at up to £0.45 billion, will be executed independently by Merrill Lynch International and is expected to be completed by September 2025, reflecting GSK’s strategic focus on optimizing shareholder value and its commitment to financial discipline.
GSK has announced the purchase of 564,381 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategy to manage the company’s capital structure and potentially enhance shareholder value, with the shares being held in treasury. Following this transaction, GSK holds 217,716,459 shares in treasury, representing 5.31% of the voting rights, and has a total of 4,097,550,815 shares in issue.
GSK has announced a transaction involving the sale of 77,000 ordinary shares by James Ford, the Senior Vice President and Group General Counsel for Legal and Compliance. The transaction was conducted on the London Stock Exchange on May 30, 2025, at a price of £14.9825 per share. This sale may impact the company’s stock performance and stakeholder perceptions, reflecting internal financial strategies or personal financial planning by the executive.
GSK plc has announced its total voting rights and capital structure as of May 31, 2025. The company reported an issued share capital of over 4.3 billion shares, with a total of approximately 4.1 billion voting rights. This information is crucial for shareholders to determine their notification obligations under the Financial Conduct Authority’s rules, impacting how they manage their interests in the company.
GSK has announced the purchase of 528,198 of its own ordinary shares, as part of its ongoing buyback program, through Citigroup Global Markets Limited. This transaction, executed on the London Stock Exchange, aims to manage the company’s capital structure and enhance shareholder value, with the shares being held in treasury. Following this purchase, GSK holds 217,152,078 shares in treasury, with a total of 4,098,115,196 shares in issue, reflecting a 5.30% voting rights attributed to treasury shares.
GSK announced that the US FDA has accepted the New Drug Application for linerixibat, a targeted inhibitor for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). The application is based on positive results from the GLISTEN phase III trial, which demonstrated significant improvement in symptoms compared to placebo. If approved, linerixibat could address a high unmet medical need for patients suffering from this debilitating condition, potentially enhancing GSK’s position in the hepatology market.
GSK has announced the purchase of 535,953 of its own ordinary shares as part of its ongoing share buyback program, executed through Citigroup Global Markets Limited. This transaction, which follows a non-discretionary agreement initiated in February 2025, increases the company’s treasury shares to 216,623,880, representing 5.29% of the total voting rights. This strategic move is likely to impact GSK’s market positioning by potentially enhancing shareholder value and optimizing capital structure.
GSK plc has announced the purchase of 535,953 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and the total number of voting rights in the company remains at 4,098,638,167. This buyback is part of a broader initiative to enhance shareholder value and optimize the company’s financial position.
GSK has announced the repurchase of 530,805 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which is part of a non-discretionary agreement, increases GSK’s treasury shares to 216,087,927, representing 5.27% of the company’s voting rights. The buyback is a strategic move to optimize capital structure and potentially enhance shareholder value.
GSK and Spero Therapeutics announced the early termination of the Phase III PIVOT-PO trial for tebipenem HBr due to its efficacy in treating complicated urinary tract infections (cUTIs). This investigational oral antibiotic could become the first oral carbapenem for cUTIs in the US, potentially reducing hospitalizations and healthcare costs. The trial’s success highlights GSK’s expanding anti-infectives portfolio and its commitment to combating antimicrobial resistance. The data will be included in a planned FDA filing in the second half of 2025.
GSK plc announced the purchase of 523,548 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a non-discretionary agreement and contributes to GSK’s strategy of managing its capital structure, with the purchased shares held as treasury shares. The buyback program is significant for shareholders as it affects the total voting rights and share distribution, with implications for shareholder notifications under the Financial Conduct Authority’s rules.
GSK has announced the repurchase of 537,661 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction increases the company’s treasury shares to 215,033,574, representing 5.2444% of the total shares with voting rights, potentially impacting shareholder calculations under the Financial Conduct Authority’s rules.
GSK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Blenrep for treating relapsed or refractory multiple myeloma in combination with other therapies. This recommendation follows successful phase III trials showing superior efficacy and safety profiles. If approved, Blenrep combinations could significantly impact treatment options for multiple myeloma, offering a new mechanism of action and addressing unmet needs in both academic and community settings. The decision by the European Commission is expected in Q3 2025, with potential implications for GSK’s market positioning and stakeholders.
GSK has announced that the US FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This approval, based on the positive results from the MATINEE and METREX phase III trials, marks a significant advancement in COPD treatment, offering hope for improved care for patients who are inadequately controlled on inhaled triple therapy. The approval is expected to impact over a million patients in the US, potentially reducing hospitalizations and emergency department visits. Mepolizumab is the only biologic approved for this patient group, providing a new treatment option for those with a blood eosinophil count starting at 150 cells/μL.
GSK has announced the purchase of 547,990 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, and the purchase contributes to the company’s broader financial strategy, impacting its total voting rights and share distribution.
GSK plc announced the purchase of 567,590 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on May 21, 2025, aims to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 213,947,923 ordinary shares in treasury, with 4,101,310,936 shares remaining in issue. The buyback program reflects GSK’s strategic financial management to optimize its capital allocation and potentially improve its stock market performance.
GSK has announced the purchase of 570,340 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and aims to enhance shareholder value by holding these shares in treasury, thereby potentially impacting the company’s market positioning and stakeholder interests.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by its Non-Executive Director, Dr. Hal Barron, and SVP and Group General Counsel, James Ford. These acquisitions were made through the reinvestment of dividends in their respective GSK savings plans. The transactions were conducted on the New York Stock Exchange, reflecting GSK’s ongoing commitment to aligning executive interests with shareholder value.
GSK has announced the purchase of 565,355 of its own ordinary shares as part of its ongoing buyback program. These shares, purchased at an average price of 1,394.81 pence, will be held in treasury, contributing to the company’s strategy to manage its capital structure effectively. This transaction reflects GSK’s commitment to returning value to shareholders and maintaining a balanced capital allocation approach.
GSK plc announced the purchase of 558,662 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at a volume-weighted average price of 1,391.34 pence, will be held as treasury shares. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited and reflects GSK’s strategy to manage its capital structure effectively. Following this transaction, GSK holds 212,244,638 shares in treasury, impacting the total voting rights available to shareholders.
GSK announced that its drug Blenrep, in combination with other treatments, has been approved by Japan’s Ministry of Health, Labour and Welfare for use in adults with relapsed or refractory multiple myeloma. This approval is based on positive results from the DREAMM-7 and DREAMM-8 phase III trials, which demonstrated superior efficacy in terms of progression-free survival and overall survival compared to standard treatments. The approval marks the second major regulatory endorsement for Blenrep combinations, following the UK’s authorization, and highlights the drug’s potential to redefine treatment outcomes for multiple myeloma patients. Blenrep’s unique mechanism as an anti-BCMA antibody-drug conjugate offers a differentiated approach, with manageable side effects, making it suitable for a wide range of patients in various treatment settings.